Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma.

Journal of immunotherapy (Hagerstown, Md. : 1997) ·Vol. 26 ·No. 2 ·2003-00-00 ·Pages 179-80

Heimann DM, Rosenberg SA

Abstract

暂无摘要

MeSH Terms

Adult Biopsy, Needle Female Follow-Up Studies Humans Immunotherapy/methods Infusions, Intravenous Male Maximum Tolerated Dose Melanoma/pathology,therapy Middle Aged Neoplasm Invasiveness/pathology Neoplasm Staging Remission Induction Salmonella Vaccines/administration & dosage Salmonella typhimurium/immunology Sampling Studies Skin Neoplasms/pathology,therapy Treatment Outcome

Chemicals

Salmonella Vaccines

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Heimann David M

Rosenberg Steven A

References (1)

1 references, click to expand

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
J Clin Oncol. 2002 Jan 1;20(1):142-52 PMID: 11773163

Article Info

Journal

Journal of immunotherapy (Hagerstown, Md. : 1997)

Abbr.

J Immunother

ISSN

1524-9557

DOI

10.1097/00002371-200303000-00011

Published

2003-00-00

Pages

179-80

Language

English

Region

United States

NLM ID

9706083

PMCID

PMC2656370

Subset

Grants

Intramural NIH HHS · Z01 SC003811-33 · United States

Corrections

CommentOn

PMID: 11773163

External Links

PubMed source DOI: 10.1097/00002371-200303000-00011 PMC Full Text View journal details

Analysis Services

Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma.

Contact

WeChat Official Account